Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rilapladib (SB 659032) is a selective inhibitor of Lipoprotein-Associated Phospholipase A2(Lp-PLA2, IC50 = 230 pM) and an antagonist of the platelet activating factor receptor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 94.00 | |
5 mg | In stock | $ 239.00 | |
10 mg | In stock | $ 389.00 | |
25 mg | In stock | $ 655.00 | |
50 mg | In stock | $ 932.00 | |
100 mg | In stock | $ 1,270.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 388.00 |
Description | Rilapladib (SB 659032) is a selective inhibitor of Lipoprotein-Associated Phospholipase A2(Lp-PLA2, IC50 = 230 pM) and an antagonist of the platelet activating factor receptor. |
Targets&IC50 | Lp-PLA2:230 pM |
In vitro | Rilapladib reduces the PAF biological activity and levels, thereby reducing Lp-PLA2 biosynthesis and preventing the possible adverse effects of Lp-PLA2 [2]. |
Synonyms | SB 659032 |
Molecular Weight | 735.8 |
Formula | C40H38F5N3O3S |
CAS No. | 412950-08-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 78 mg/mL (106 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Rilapladib 412950-08-4 Metabolism Phospholipase SB659032 SB-659032 SB 659032 inhibitor inhibit